Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Impact of Ad Exposure Frequency on Perception and Mental Processing of Risks and Benefit Information in Direct-to-Consumer Prescription Drug Ads, 66912 [2015-27743]
Download as PDF
<![CDATA[
66912
Federal Register / Vol. 80, No. 210 / Friday, October 30, 2015 / Notices
discontinued marketing of the products
subject to those NDAs and ANDAs.
Additional ANDAs that refer to these
products may also be approved by the
Agency if they comply with relevant
legal and regulatory requirements. If
FDA determines that labeling for these
drug products should be revised to meet
current standards, the Agency will
advise ANDA applicants to submit such
labeling.
Dated: October 26, 2015.
Leslie Kux,
Associate Commissioner for Policy.
has assigned OMB control number
0910–0803. The approval expires on
September 30, 2018. A copy of the
supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
Dated: October 26, 2015.
Leslie Kux,
Associate Commissioner for Policy.
Dated: October 26, 2015.
Leslie Kux,
Associate Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–27743 Filed 10–29–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–27740 Filed 10–29–15; 8:45 am]
BILLING CODE 4164–01–P
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2014–N–1491]
Food and Drug Administration
[Docket No. FDA–2014–N–1794]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Impact of Ad Exposure Frequency on
Perception and Mental Processing of
Risks and Benefit Information in
Direct-to-Consumer Prescription Drug
Ads
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Impact of Ad Exposure Frequency on
Perception and Mental Processing of
Risks and Benefit Information in Directto-Consumer Prescription Drug Ads’’
has been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On June
29, 2015, the Agency submitted a
proposed collection of information
entitled ‘‘Impact of Ad Exposure
Frequency on Perception and Mental
Processing of Risks and Benefit
Information in Direct-to-Consumer
Prescription Drug Ads’’ to OMB for
review and clearance under 44 U.S.C.
3507. An Agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number. OMB has now
approved the information collection and
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:37 Oct 29, 2015
Jkt 238001
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Survey of Pharmacists and Patients;
Variations in the Physical
Characteristics of Generic Drug Pills
and Patient Perceptions
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Survey of Pharmacists and Patients;
Variations in the Physical
Characteristics of Generic Drug Pills and
Patient Perceptions’’ has been approved
by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On May
28, 2015, the Agency submitted a
proposed collection of information
entitled ‘‘Survey of Pharmacists and
Patients; Variations in the Physical
Characteristics of Generic Drug Pills and
Patient Perceptions’’ to OMB for review
and clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0801. The
approval expires on September 30,
2018. A copy of the supporting
statement for this information collection
is available on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
SUMMARY:
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
[FR Doc. 2015–27742 Filed 10–29–15; 8:45 am]
BILLING CODE 4164–01–P
Performance Review Board Members
Title 5, U.S.C. Section 4314(c)(4) of
the Civil Service Reform Act of 1978,
Public Law 95–454, requires that the
appointment of Performance Review
Board Members be published in the
Federal Register.
The following persons may be named
to serve on the Performance Review
Boards or Panels, which oversee the
evaluation of performance appraisals of
Senior Executive Service members of
the Department of Health and Human
Services.
Employee last name
Agrawal .....................
Atkinson ....................
Boulanger ..................
Bowers ......................
Burton ........................
Cannistra ...................
Cantwell ....................
Carter ........................
Cavanaugh ................
Cheatham ..................
Cheever .....................
Conway .....................
Counihan ...................
Dammons ..................
Devoss ......................
Espinosa ...................
Etziner .......................
Garcia ........................
Garner .......................
Goldhaber .................
Goodman ..................
Hamilton ....................
Hammarlund ..............
Handley .....................
Hartstein ....................
Haseltine ...................
Hattery .......................
Heffler ........................
Hill .............................
Jackson .....................
Kane ..........................
Kavanagh ..................
Kerr ...........................
Killoran ......................
Kramer ......................
Kretschmaier .............
Lewis .........................
Lodes ........................
Lu ..............................
Macrae ......................
Malcomson ................
Mills ...........................
Montilla ......................
Moody-Williams .........
Morris ........................
Murray .......................
E:\FR\FM\30OCN1.SGM
30OCN1
Employee first name
Shantanu
Leslie
Jennifer
Tonya
Adriane
Jennifer
Kathleen
Cathy
Sean
Tina
Laura
Patrick
Keven
Cheryl
Elizabeth
Diana
Michael
Alexandra
Jacqueline
Ben
Richard
Thomas
John
Elisabeth
Marc
Amy
Debbra
Stephen
Timothy
Karen
Daniel
Laura
James
Beth
Martin
Michon
Lisa
Lori
Michael
James
Dennis
George
Maria
Jean
Thomas
Renard
]]>Agencies
[Federal Register Volume 80, Number 210 (Friday, October 30, 2015)]
[Notices]
[Page 66912]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-27743]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-1794]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Impact of Ad Exposure Frequency on
Perception and Mental Processing of Risks and Benefit Information in
Direct-to-Consumer Prescription Drug Ads
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Impact of Ad Exposure Frequency on
Perception and Mental Processing of Risks and Benefit Information in
Direct-to-Consumer Prescription Drug Ads'' has been approved by the
Office of Management and Budget (OMB) under the Paperwork Reduction Act
of 1995.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On June 29, 2015, the Agency submitted a
proposed collection of information entitled ``Impact of Ad Exposure
Frequency on Perception and Mental Processing of Risks and Benefit
Information in Direct-to-Consumer Prescription Drug Ads'' to OMB for
review and clearance under 44 U.S.C. 3507. An Agency may not conduct or
sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB control number.
OMB has now approved the information collection and has assigned OMB
control number 0910-0803. The approval expires on September 30, 2018. A
copy of the supporting statement for this information collection is
available on the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: October 26, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-27743 Filed 10-29-15; 8:45 am]
BILLING CODE 4164-01-P
